OxCD3: Oxford Centre for Drug Delivery Devices

肿瘤学药物输送的最大挑战是实现治疗剂在整个肿瘤中的成功渗透和分布：迄今已花费数十亿英镑部署生化方法，试图解决本质上是一个工程问题，即将治疗药物从血液输送到每一个癌细胞。OxCD3将寻求通过展示工程方法的价值和可行性来改变药物输送的临床和行业实践，工程方法涉及刺激反应纳米载体和已经在临床使用的医疗设备的组合，以改善肿瘤的摄取和治疗结果。该计划补助金将为生物、化学和医疗设备的组合工程创造一个可持续的、世界独特的多学科环境，以改善在同一屋檐下的药物输送。预计它还将通过直接接触将实验室研究转化为生产和临床实践时遇到的监管和制造问题，为从事联合疗法和生物医学纳米技术的下一代年轻科学家创造一个独特的培训环境。该中心的一个独特之处是能够在同一屋檐下设计设备和药物运送工具。在头5年，在EPSRC的资助下，最多3个精心挑选的“设备+药物”样本将按照GMP标准制造，准备进行第一阶段临床试验，为行业合作伙伴和临床医生提供令人信服的可行性证据；在未来5年，将建立公私合作伙伴关系，使用对制药业具有战略意义的疗法完成这些样本的临床试验；10年后，预计OXCD3将得到行业的全面赞助，该计划将专注于与行业和临床医生合作，应对下一代药物输送(癌症以外)的挑战。50年来的变革性目标是将英国定位为多学科药物输送开发的世界领先者，补充其现有的从设计到制造和临床试验的药物发现领先者的地位。

The greatest challenge in oncological drug delivery is achieving successful penetration and distribution of the therapeutic agent throughout the tumour: billions of pounds have been spent to date in deploying biochemical approaches in an attempt to solve what is essentially an engineering problem, namely the transport of therapeutics from the blood stream to reach every cancer cell. OxCD3 will seek to transform both clinical and industry practice in drug delivery by demonstrating the value and feasibility of engineering approaches, involving a combination of stimulus-responsive nanocarriers and medical devices already in clinical use, for improved tumour uptake and therapeutic outcome. The Programme Grant will enable the creation of a sustainable, world-unique multi-disciplinary environment for combinational engineering of biology, chemistry and medical devices to improve drug delivery under a single roof. It is also expected to create a unique training environment for the next generation of young scientists working on combination therapies and biomedical nanotechnology, by providing direct exposure to regulatory and manufacturing issues encountered when translating laboratory research into production and clinical practice. A unique feature of the Centre is the capability to design both devices and drug delivery vehicles under a single roof. In the first 5 years, under EPSRC funding, up to 3 carefully selected "Device+Drug" exemplars will be manufactured to GMP, ready for Phase I clinical trials, to provide compelling evidence of feasibility to industrial partners and clinicians; in the next 5 years, a private-public partnership will be built to complete clinical trials of these exemplars using therapeutics of strategic significance to the pharmaceutical industry; beyond 10 years, full industrial sponsorship of the OXCD3 is anticipated, which will focus on addressing next-generation challenges in drug delivery (beyond cancer) in partnership with industry and clinicians. The transformative aim over 50 years is to position the UK as the world leader for multi-disciplinary drug delivery development, complementing its existing position as a drug discovery leader, from design to manufacture and clinical trials.